# Phase 1/2 Carcinoma, Non-Small-Cell Lung trials: 185 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 185 trials in phase 1/2 for Carcinoma, Non-Small-Cell Lung that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Carcinoma, Non-Small-Cell Lung trials: 185 rows for $9.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/carcinoma-non-small-cell-lung

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 185
- Recruiting or not yet: 185
- Read on: November 19, 2026

## Trials

The 25 newest of 185, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947134 | A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours | GlaxoSmithKline | Phase 1/2 | Not yet recruiting | Solid Tumours | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947134) |
| November 16, 2026 | NCT07939815 | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Bristol-Myers Squibb | Phase 1/2 | Not yet recruiting | Advanced Solid Malignancies | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939815) |
| November 12, 2026 | NCT07933055 | Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan... | Txinno Bioscience Inc. | Phase 1/2 | Recruiting | NSCLC (Non-small Cell Lung Cancer) | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933055) |
| November 3, 2026 | NCT07912593 | A KRAS Inhibitor in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer... | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912593) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| October 29, 2026 | NCT07902921 | STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic... | National Cancer Institute (NCI) | Phase 1/2 | Not yet recruiting | NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer, Thymic Epithelial Tumors, TETs, Thymic Carcinomas... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902921) |
| October 22, 2026 | NCT07890714 | A Study of Dato-DXd in Participants With Solid Tumors \[TROPION-PanTumor04 (TP04)\] | Daiichi Sankyo | Phase 1/2 | Recruiting | Urothelial Cancer, Non-small Cell Lung Cancer | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890714) |
| October 22, 2026 | NCT07889232 | Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer | VA Office of Research and Development | Phase 1/2 | Not yet recruiting | Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889232) |
| October 14, 2026 | NCT07873450 | SumMET: Study of \[225Ac\]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Full-Life Technologies UK Limited | Phase 1/2 | Recruiting | Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer, Cholangiocarcinoma | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873450) |
| October 8, 2026 | NCT07864584 | Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced... | Nob Hill Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864584) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| September 29, 2026 | NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of... | Genfleet Therapeutics (Shanghai) Inc. | Phase 1/2 | Not yet recruiting | RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846358) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07751042 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Strand Therapeutics Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751042) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 4, 2026 | NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | Iovance Biotherapeutics, Inc. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743723) |
| July 31, 2026 | NCT07739966 | A Study of DS-3939a in Participants With Solid Tumors | Daiichi Sankyo | Phase 1/2 | Recruiting | Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739966) |
| July 21, 2026 | NCT07718243 | Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC | Institute of Cancer Research, United Kingdom | Phase 1/2 | Recruiting | Melanoma (Skin Cancer), Non Small Cell Lung Cancer, Solid Tumor in Advanced Stage | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718243) |
| July 13, 2026 | NCT07699328 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer | Voronoi, Inc | Phase 1/2 | Recruiting | EGFR-Mutant Non-Small Cell Lung Cancer | 315 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699328) |
| July 7, 2026 | NCT07688577 | XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors | Xilio Development, Inc. | Phase 1/2 | Recruiting | Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688577) |
| June 26, 2026 | NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | XYone Therapeutics, Inc | Phase 1/2 | Recruiting | MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ... | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670312) |
| June 18, 2026 | NCT07655622 | Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression | Second Affiliated Hospital of Nanchang University | Phase 1/2 | Recruiting | Non-Small-Cell Lung Cancer | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07655622) |
| June 11, 2026 | NCT07641023 | Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC | Beijing Biotech | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer, Advanced/Metastatic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641023) |
| June 9, 2026 | NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | VM Discovery, Inc. | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer... | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636785) |
| June 8, 2026 | NCT07632365 | Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced... | Shanghai Chest Hospital | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632365) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 4 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 4 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 4 |
| Shanghai Chest Hospital | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| DualityBio Inc. | 3 |
| [Pierre Fabre Medicament](https://specstream.ai/data/clinical-trials/company/pierre-fabre-medicament) | 3 |
| [Shanghai JMT-Bio Inc.](https://specstream.ai/data/clinical-trials/company/shanghai-jmt-bio-inc) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Hummingbird Bioscience | 2 |
| Avistone Biotechnology Co., Ltd. | 2 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 2 |
| Essen Biotech | 2 |
| Cancer Research UK | 2 |
| St. Joseph's Healthcare Hamilton | 2 |
| VA Office of Research and Development | 2 |
| [Betta Pharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/betta-pharmaceuticals-co-ltd) | 2 |
| [Yuhan Corporation](https://specstream.ai/data/clinical-trials/company/yuhan-corporation) | 2 |
| National Cancer Institute (NCI) | 2 |
| Iovance Biotherapeutics, Inc. | 2 |
| [Allist Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/allist-pharmaceuticals-inc) | 2 |
| [MediLink Therapeutics (Suzhou) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/medilink-therapeutics-suzhou-co-ltd) | 2 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 2 |
| [Dizal Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/dizal-pharmaceuticals) | 2 |
| Henan Genuine Biotech Co., Ltd. | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 108 |
| China | 61 |
| Australia | 33 |
| Spain | 33 |
| France | 25 |
| Taiwan | 24 |
| South Korea | 22 |
| United Kingdom | 20 |
| Italy | 20 |
| Japan | 17 |
| Canada | 15 |
| Germany | 14 |
| Belgium | 12 |
| Netherlands | 11 |
| Poland | 8 |
| Turkey (Türkiye) | 7 |
| Singapore | 7 |
| Puerto Rico | 5 |
| Denmark | 5 |
| Hong Kong | 4 |
| Israel | 4 |
| Argentina | 3 |
| Brazil | 3 |
| Malaysia | 3 |
| Moldova | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Gluten free restaurants in the United States](https://specstream.ai/data/businesses/gluten-free-restaurants/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
- [Driving schools in the United States](https://specstream.ai/data/businesses/driving-schools/united-states)
- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
- [Business financing companies in the United States](https://specstream.ai/data/businesses/business-financing-companies/united-states)
- [Medical schools in the United States](https://specstream.ai/data/businesses/medical-schools/united-states)
